In a mouse model of lung cancer, triple therapy via addition of the targeted therapy anlotinib [which inhibits the vascular endothelial growth factor receptor (VEGFR)] to radiotherapy and immunotherapy (anti-PD-L1 immune checkpoint inhibition), reduced MDSCs and Arg1 levels resulting in significantly more CD8+ T cell infiltration, heightened IFNγ expression, and lower tumour burden compared to without anlotinib [47]. Here, ARG1 is linked to lung cancer.